Esperion(US:ESPR)2025-03-04 12:26Financial Guidance - For the fiscal year ending December 31, 2025, research & development expenses are expected to be in the range of $55 million to $65 million[5] - Selling, general and administrative expenses are projected to be between $160 million and $170 million[5] - Total operating expenses are anticipated to be in the range of $215 million to $235 million[5] - The financial guidance reflects management's current expectations for the business[5] - The company presented this financial guidance at the 43rd Annual J.P. Morgan Healthcare Conference[5] Forward-Looking Statements - Forward-looking statements include expectations about full year expenses and financial performance[6] - Actual results may differ materially from the forward-looking statements due to estimates, assumptions, and uncertainties[6] - The company disclaims any obligation to update or revise forward-looking statements, except as required by law[6] Presentation and Reporting - Selected slides from the presentation are attached as Exhibit 99.1 to the Current Report[5] - The report was signed by Sheldon L. Koenig, President and CEO, on January 16, 2025[11]